Xuzhou Wanbang Jinqiao Pharma Co., Ltd.(hereinafter referred to as WB Jinqiao), formerly the API manufacturing division of Jiangsu Wanbang Biopharmaceuticals (Group) (hereinafter referred to as Wanbang Biopharma), was incorporated into a joint venture company in September 2006 as the holding subsidiary of Wanbang Biopharma. WB Jinqiao is mainly engaged in the R&D, production and sales of API, now the only animal-derived insulin manufacturer in China, high-tech enterprise in Jiangsu Province, Xuzhou Engineering Technology Research Center. It was certified by OHSAS 18001:2007 in 2010 and ISO14001:2015 in 2017. The company's products cover fields like hyperglycemia, hypertension, hyperlipidemia, hyperuricemia, anti-tumor and other therapeutic fields. The listed APIs include insulin, glimepiride, pitavastatin calcium, febuxostat, and fasudil hydrochloride. Among them, the domestic preparations market share of insulin, glimepiride, and febuxostat ranks first. With the mission of "We are dedicated to a healthier life", WB Jinqiao provides customers with products in accordance with regulations and with stable quality. The company continues to innovate, vigorously introduces and cultivates talents, provides employees with better space for learning, growth and development. In addition, WB Jinqiao actively fulfills its corporate social responsibilities, promotes the continuous improvement of EHS system, safety production, energy conservation and emission reduction, protects the homeland with greenery.